Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions.

Hdl Handle:
http://hdl.handle.net/10144/23753
Title:
Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions.
Authors:
Bausch, D G; Sprecher, A G; Jeffs, B; Boumandouki, P
Journal:
Antiviral Research
Abstract:
The filoviruses, Marburg and Ebola, have the dubious distinction of being associated with some of the highest case-fatality rates of any known infectious disease-approaching 90% in many outbreaks. In recent years, laboratory research on the filoviruses has produced treatments and vaccines that are effective in laboratory animals and that could potentially drastically reduce case-fatality rates and curtail outbreaks in humans. However, there are significant challenges in clinical testing of these products and eventual delivery to populations in need. Most cases of filovirus infection are recognized only in the setting of large outbreaks, often in the most remote and resource-poor areas of sub-Saharan Africa, with little infrastructure and few personnel experienced in clinical research. Significant political, legal, and socio-cultural barriers also exist. Here, we review the present research priorities and environment for field study of the filovirus hemorrhagic fevers and outline a strategy for future prospective clinical research on treatment and vaccine prevention.
Affiliation:
Tulane University Health Sciences Center, New Orleans, LA, United States.
Issue Date:
Apr-2008
URI:
http://hdl.handle.net/10144/23753
DOI:
10.1016/j.antiviral.2008.01.152
PubMed ID:
18336927
Additional Links:
http://www.sciencedirect.com/science/journal/01663542.
Language:
en
ISSN:
0166-3542
Appears in Collections:
Other Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorBausch, D G-
dc.contributor.authorSprecher, A G-
dc.contributor.authorJeffs, B-
dc.contributor.authorBoumandouki, P-
dc.date.accessioned2008-04-18T10:56:59Z-
dc.date.available2008-04-18T10:56:59Z-
dc.date.issued2008-04-
dc.identifier.citationTreatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. 2008, 78 (1):150-61 Antiviral Res.en
dc.identifier.issn0166-3542-
dc.identifier.pmid18336927-
dc.identifier.doi10.1016/j.antiviral.2008.01.152-
dc.identifier.urihttp://hdl.handle.net/10144/23753-
dc.description.abstractThe filoviruses, Marburg and Ebola, have the dubious distinction of being associated with some of the highest case-fatality rates of any known infectious disease-approaching 90% in many outbreaks. In recent years, laboratory research on the filoviruses has produced treatments and vaccines that are effective in laboratory animals and that could potentially drastically reduce case-fatality rates and curtail outbreaks in humans. However, there are significant challenges in clinical testing of these products and eventual delivery to populations in need. Most cases of filovirus infection are recognized only in the setting of large outbreaks, often in the most remote and resource-poor areas of sub-Saharan Africa, with little infrastructure and few personnel experienced in clinical research. Significant political, legal, and socio-cultural barriers also exist. Here, we review the present research priorities and environment for field study of the filovirus hemorrhagic fevers and outline a strategy for future prospective clinical research on treatment and vaccine prevention.en
dc.language.isoenen
dc.relation.urlhttp://www.sciencedirect.com/science/journal/01663542.-
dc.rightsArchived with kind permission of Elsevieren
dc.titleTreatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions.en
dc.contributor.departmentTulane University Health Sciences Center, New Orleans, LA, United States.en
dc.identifier.journalAntiviral Researchen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.